Telomerase is a ribonucleoprotein polymerase that synthesizes telomeric repeats onto the 3′ ends of eukaryotic chromosomes. Activation of telomerase may prevent telomeric shortening and correlates with cell immortality in the germline and certain tumor cells. Candidate hematopoietic stem cells (HSC) from adult bone marrow express low levels of telomerase, which is upregulated with proliferation and/or differentiation. To address this issue, we stimulated purified candidate HSC from human adult bone marrow with stem cell factor (SCF), interleukin-3 (IL-3), and Flt3-ligand (FL). After 5 days in culture, activity was detected in total cell extracts from IL-3–, SCF + FL–, SCF + IL-3–, FL + IL-3–, and SCF + IL-3 + FL–stimulated cultures, but not from cells cultured in SCF or FL alone. Within the CD34+fraction of the cultured cells, significant activity was found in the CD34+CD71+ fraction. In addition, PKH26 staining confirmed that detectable telomerase activity was present in dividing PKH26lo cells, whereas nondividing PKH26hi cells were telomerase negative. Because in these experiments no distinction could be made between cycling “candidate” stem cells that had retained or had lost self-renewal properties, fetal liver cells with a CD34+CD38 phenotype, highly enriched for cycling stem cells, were also examined and found to express readily detectable levels of telomerase activity. Given the replication-dependent loss of telomeric DNA in hematopoietic cells, these observations suggest that the observed telomerase activity in candidate stem cells is either expressed in a minor subset of stem cells or, more likely, is not sufficient to prevent telomere shortening.

THE ENDS OF all eukaryotic chromosomes are organized into telomeres that consist of tandem arrays of G-rich repeats and associated proteins. Telomeres protect chromosomes from degradation, prevent end-to-end fusions, and position chromosomes within the nucleus.1,2 In primary somatic cells such as fibroblasts,3,4 lymphocytes,5 or hematopoietic progenitors,6 telomeric DNA is gradually lost with each cell division presumably because conventional DNA polymerases cannot fully replicate the ends of linear chromosomes.7,8Progressive shortening of chromosome ends has been suggested to act as a mitotic clock that may contribute to cellular senescence and eventual cell mortality of normal mammalian somatic cells.9 

On the other hand, cells of the germ line, such as sperm cells, have long telomeres of 10 to 20 kb that do not appear to shorten with aging of the organism.4 Such long telomeric ends are assumed to be maintained by telomerase, a ribonucleoprotein whose primary function is to synthesize telomeric DNA, thus counteracting losses at the chromosome termini with each round of replication. The telomerase RNA component contains a species-specific template for synthesis of telomeric repeats, and such RNA sequences have been cloned from ciliates,10 yeast,11,12 mouse,13and human.14 Recently, the gene encoding the reverse transcriptase catalytic subunit of telomerase from several species including humans has also been cloned.15,16 In humans, telomerase activity is readily detectable in testes and ovaries, but not in most somatic tissues.17,18 Telomerase activity is also elevated in carcinomas of the ovary,19breast,20 liver,21 lung,22prostate,23 and in neuroblastoma24 and hematological malignancies.25-27 In addition, the majority of immortal cell lines expresses telomerase, whereas most mortal cells lack this activity.17 Together, these data strongly suggest that telomerase may be involved in malignant transformation and cellular immortality.

The hematopoietic system replenishes the loss of mature blood cells via the recruitment of stem cells that have been defined as pluripotential cells with self-renewal properties. We and others have shown low levels of telomerase activity in normal bone marrow and peripheral blood cells, both in progenitors of the myeloid and lymphoid lineages as well as in terminally differentiated cells such as T and B cells.26-28 Furthermore, we and others found that “candidate” hematopoietic stem cells (HSC) upregulate telomerase activity upon stimulation in vitro.28,29 However, as the vast majority of stem cells are quiescent during steady-state hematopoiesis,30 the status of telomerase expression in cycling HSC has not yet been elucidated. This is an important issue because the self-renewal and replicative potential of the most primitive hematopoietic cells may depend on telomerase to maintain stable telomeres.31 In this report, we describe results of experiments designed to address the question of telomerase expression in cycling stem cells. For this purpose, we measured telomerase activity in extracts from purified candidate HSC from human adult bone marrow stimulated with different cytokines and in extracts from CD34+CD38 candidate HSC purified from human fetal liver. Our data indicated that telomerase activity is expressed in most if not all cycling stem cells but is repressed in quiescent stem cells.

Purification of HSC from adult bone marrow and fetal liver.

Candidate HSC with the phenotype CD34+CD45RAloCD71lo were obtained from previously frozen cadaver marrow as previously described.32 Briefly, mononuclear cells retrieved from the interface after density separation were stained with 8G12-Cy5 (anti-CD34), 8d2-PE (anti-CD45RA), and OKT9-FITC (anti-CD71) for 30 minutes at 4°C. Cells were washed twice in Hanks' buffered saline with 0.2% BSA (HB) and stained with 2 μg/mL of propidium iodide (PI) before suspending in HB at a density of 5 × 106 cells/mL for sorting. Cells were sorted on a FACStarplus (Becton Dickinson, San Jose, CA) equipped with argon (488 nm) and helium-neon (633 nm) lasers.

CD34+CD45RAloCD71loCD38(CD34+CD38) cells were obtained from adult marrow and fetal liver in the 17th and 18th week of gestation according to previously described protocols.33 34 Cells were stained with 8G12-Cy5, 8d2-FITC, OKT9-FITC, and anti–CD38-phycoerythrin (PE; Becton Dickinson) for 30 minutes at 4°C. The washing and sorting procedures were performed as above.

Cell culture.

Sorted candidate HSC were cultured in serum-free medium consisting of Iscove's modified Dulbecco's medium (IMDM) supplemented with the following reagents: bovine serum albumin (BSA) at 2%, sodium bicarbonate at 0.1%, transferrin at 200 μg/mL, insulin at 10 μg/mL, 2-mercaptoethanol at 10−5 mol/L, low-density lipoprotein (Sigma, St Louis, MO) at 40 μg/mL, and penicillin-streptomycin at 100 U and 50 μg/mL, respectively.32 Both stem cell factor (SCF) and Flt3-ligand (FL) were used at a final concentration of 50 ng/mL, whereas interleukin-3 (IL-3) was used at 20 ng/mL. All growth factors were purchased from Pepro-tech (Rocky Hill, NJ).

Telomerase repeat amplification protocol (TRAP) assay.

Telomerase activity was measured by TRAP assay using an end-labeled telomerase substrate (TS) primer as described.17,27,28Briefly, cell extracts were prepared by lysing the cells in CHAPS extraction buffer17 at a concentration of 500 cells per μL of buffer, centrifuged at 1200g at 4°C, and 2 μL of these extracts were used in the assay.

The telomerase reaction was performed in 50 μL of TRAP reaction buffer containing 20 mmol/L tris-HCl (pH 8.3), 1.5 mmol/L MgCl2, 63 mmol/L KCl, 0.005% Tween-20, 1 mmol/L EGTA, 50 μmol/L deoxynucleotide triphosphates (Pharmacia, Uppsala, Sweden), 0.1 μg each of the labeled TS primer, ACX primer, U2 primer, 5 × 10−3 attamoles (amols) of an internal control primer (TSU2), 2 U of Taq DNA polymerase (Boehringer Mannheim, Laval, Quebec), and 2 μL of CHAPS extract. The primers for this reaction are obtainable through Oncor (Gaithersburg, MD). Reaction tubes were placed in a robocycler (Stratagene, La Jolla, CA) for 30 minutes at 30°C, followed by 27 cycles of polymerase chain reaction (PCR) at 94°C for 30 seconds and 72°C for 30 seconds. One half of the amplified products were resolved on a 12% polyacrylamide gel, dried, and visualized by autoradiography using BioMax films (Kodak, Rochester, NY) after 48 hours of exposure at room temperature. In some cases, RNase A (Boehringer Mannheim) at 6 μg/mL was added during the telomerase reaction to confirm the specificity of the telomerase products that disappeared in the presence of RNase A.

For semiquantitative analysis of telomerase activity, the radioactive bands were scanned by densitometer and determined using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). The signal from individual test extract was normalized for the PCR efficiency and compared with that generated by 1 amol of an oligonucleotide M2R8, which contains the same sequence as the TS primer plus eight T2AG3 repeats using the following formula:

whereLB is the blank control containing 2 μL of CHAPS lysis buffer in lieu of cell extract.

Tracking proliferation by PKH26 staining.

The proliferative history of cells was followed using PKH26 labeling and analysis as described.30 Sorted candidate HSC were washed once in Hanks' buffered saline without BSA. The cell pellet was resuspended in 150 μL of dilutent C (Zynaxis Cell Science, Malvern, PA), mixed with an equal volume of PKH26-GL (2 × 10−6mol/L), and incubated for 5 minutes at room temperature. The reaction was terminated by the addition of an equal volume of 10% BSA in serum-free medium. Cells were washed twice and an aliquot was taken for analysis of PKH26 staining intensity on day 0 of culture. PKH26 was excited at 488 nm and the emission was measured with a 575/26 filter. The remainder of the cells was put in culture under serum-free conditions supplemented with SCF, IL-3, and FL for 8 days. After 8 days of culture, cells were reanalyzed and sorted for PKHhi and PKHlo cells using FACStarplus.

Telomerase activity in candidate stem cells from adult bone marrow.

Cell extracts from adult marrow candidate HSC with the phenotype CD34+CD45RAloCD71lo were assayed for telomerase activity by a modified version of the PCR-based TRAP assay. In addition to the typical ladder of 6 bp repeats that correspond to the amplified product of the TS primer, an internal control (TSU2) is coamplified that yields a single lower band of 35 bp (Fig 1). By normalizing the signal intensity of the telomerase ladder to that of the internal control, sample to sample variation due to PCR amplification efficiency was minimized, thus allowing for semiquantitative analysis. Treatment with RNase obliterated the 6-bp ladder, indicating that telomerase was responsible for this reaction (Fig 1). This modified TRAP assay allowed us to detect telomerase activity in cell extracts obtained from 10 to 100 cell equivalent of 293 cells, a telomerase-positive immortalized kidney cell line.

Fig. 1.

Telomerase activity in candidate HSC before culture. TRAP products were generated from 2 μL of CHAPS extract (1,000 cell equivalents) in the presence (+) or absence (−) of RNase A. TRAP products generated from sorted cells on day 0 from 4 different cadaveric marrow (lanes 1 to 8); lane 9, no extract; lane 10, 1 amol M2R8 standard. Arrow indicates the position of the 35-bp amplified internal control.

Fig. 1.

Telomerase activity in candidate HSC before culture. TRAP products were generated from 2 μL of CHAPS extract (1,000 cell equivalents) in the presence (+) or absence (−) of RNase A. TRAP products generated from sorted cells on day 0 from 4 different cadaveric marrow (lanes 1 to 8); lane 9, no extract; lane 10, 1 amol M2R8 standard. Arrow indicates the position of the 35-bp amplified internal control.

Close modal

Low levels of telomerase activity were detected in candidate HSC from four different marrow samples (Fig 1). The telomerase levels in the purified candidate HSC varied from 3% to 20% of that generated by 1 amol of M2R8, an oligonucleotide with 8 T2AG3repeats used as a quantitation standard, which translated to an equivalent of 0.06% to 0.4% of the activity of 293 cells when normalized on a per-cell basis.

Telomerase activity in candidate HSC after culture in cytokine combinations of SCF, FL, and IL-3.

Because telomerase activity was reported to increase upon cellular activation,29 35-37 candidate HSC were cultured in the presence of SCF, IL-3, and FL to examine potential upregulation of telomerase activity. When the purified cells were cultured in SCF or FL alone for 5 days, no upregulation of telomerase activity was observed, whereas IL-3 by itself enhanced telomerase activity (Fig2). Among combinations of two cytokines, those containing IL-3 (SCF + IL-3 or FL + IL-3) were more effective in upregulating telomerase activity than the combination SCF + FL, giving rise to a twofold increase in telomerase activity (Fig 2). Total cell extracts derived from candidate HSC cultured in the presence of SCF + IL-3 + FL also showed enhanced telomerase activity (Fig 2). The relatively low levels of telomerase activity did not appear to result from inhibitory substances to the PCR reaction because the internal control was amplified as expected (Fig 2). Furthermore, mixing extracts from hematopoietic cells with those from 293 cells did not result in any significant decrease in 293 telomerase activity, further indicating that inhibitors of telomerase were unlikely to be present (data not shown).

Fig. 2.

Telomerase activity in candidate HSC after 5 days of culture. TRAP products using CHAPS extracts of total viable cells derived by culturing purified candidate HSC from BM4 for 5 days in SCF (lanes 1 and 2), FL (lanes 3 and 4), IL-3 (lanes 5 and 6), SCF + FL (lanes 7 and 8), SCF + IL-3 (lanes 9 and 10), FL + IL-3 (lanes 11 and 12), and SCF + FL +

IL-3 (lanes 13 and 14). TRAP products were resolved on a 15% polyacrylamide gel, dried, and exposed to film for 48 hours. The intensity of the signals was analyzed by a densitometer using ImageQuant program and normalized to that of the internal control. Cellular extracts from BM1 and BM3 yielded similar results.

Fig. 2.

Telomerase activity in candidate HSC after 5 days of culture. TRAP products using CHAPS extracts of total viable cells derived by culturing purified candidate HSC from BM4 for 5 days in SCF (lanes 1 and 2), FL (lanes 3 and 4), IL-3 (lanes 5 and 6), SCF + FL (lanes 7 and 8), SCF + IL-3 (lanes 9 and 10), FL + IL-3 (lanes 11 and 12), and SCF + FL +

IL-3 (lanes 13 and 14). TRAP products were resolved on a 15% polyacrylamide gel, dried, and exposed to film for 48 hours. The intensity of the signals was analyzed by a densitometer using ImageQuant program and normalized to that of the internal control. Cellular extracts from BM1 and BM3 yielded similar results.

Close modal
Telomerase activity in cultured candidate HSC is restricted to cycling cells.

Because telomerase activity was upregulated in cultures containing IL-3, SCF + IL-3, FL + IL-3, and SCF + FL + IL-3, we next investigated whether increased levels of telomerase activity were restricted to cells of a particular phenotype. Flow cytometric analysis of purified candidate HSC after 5 days of culture in the seven different cytokine combinations revealed that in cultures with SCF or FL alone, the majority of cells retained the CD34+CD45RAloCD71lo phenotype (Fig3). On the other hand, in cultures containing IL-3, the percentage of CD34+CD45RAloCD71lo cells decreased to below 50% of total viable cells (Table1), and increased numbers of CD34, CD34+CD45RAloCD71hi, and CD34+CD45RAhiCD71hi cells were observed (Fig 3, Table 1). Candidate HSC cultured for 5 days in SCF + FL + IL-3 were sorted into CD34, CD34+, CD34+CD45RAloCD71lo, CD34+CD45RAloCD71hi, and CD34+CD45RAhiCD71hi cells. Semiquantitative analysis of telomerase activity indicated that CD34+ cells expressed fourfold higher levels than those in the CD34 cells (Fig 4).Among the CD34+ cells, most telomerase activity resided in the CD34+CD45RAloCD71hi and CD34+CD45RAhiCD71hipopulations, whereas CD34+CD45RAloCD71lo cells had negligible telomerase activity (Fig 4).

Fig. 3.

Phenotypic analysis of candidate HSC after culture. Candidate HSC were cultured for 5 days in (A) SCF, (B) FL, (C) IL-3, (D) SCF + FL, (E) SCF + IL-3, (F) FL + IL-3, and (G) SCF + FL + IL-3. After 5 days, cells were stained with antibodies against CD34, CD45RA, and CD71. Profiles shown were from events gated for low PI, low SCC, and high expression of CD34. In (G) boxes I, II, and III represent the windows used to sort for CD34+CD45RAloCD71lo cells, CD34+CD45RAloCD71hi cells, and CD34+CD45RAhiCD71hi cells, respectively. The same windows were applied to Fig 4 and Table 1.

Fig. 3.

Phenotypic analysis of candidate HSC after culture. Candidate HSC were cultured for 5 days in (A) SCF, (B) FL, (C) IL-3, (D) SCF + FL, (E) SCF + IL-3, (F) FL + IL-3, and (G) SCF + FL + IL-3. After 5 days, cells were stained with antibodies against CD34, CD45RA, and CD71. Profiles shown were from events gated for low PI, low SCC, and high expression of CD34. In (G) boxes I, II, and III represent the windows used to sort for CD34+CD45RAloCD71lo cells, CD34+CD45RAloCD71hi cells, and CD34+CD45RAhiCD71hi cells, respectively. The same windows were applied to Fig 4 and Table 1.

Close modal
Table 1.

Cytokine Mixtures Used to Stimulate the Proliferation and Differentiation of Candidate HSC

Percentages of Viable Cells With the Following Phenotype
Cytokine ConditionsNumber of ExptsFold Increase*3434+45lo71lo34+45lo71hi34+45hi71hi
SCF 3  0.27 ± 0.14-151 7 ± 4  79 ± 6  4 ± 2  1 ± 1  
FL  2  0.21, 0.15-151 20, 11  62, 66  3, 13  1, 4  
IL-3  0.56 ± 0.17  46 ± 14  29 ± 15  19 ± 6 3 ± 2  
SCF + FL  3  0.43 ± 0.17  9 ± 4 56 ± 14  14 ± 7  12 ± 6   
SCF + IL-3  1.48 ± 0.88  31 ± 17  47 ± 19  24 ± 9 8 ± 4  
FL + IL-3  2  2.9, 1.9  17, 57 31, 13  33, 22  14, 6  
SCF + IL-3 + FL 5  1.96 ± 1.05  24 ± 14  19 ± 9  29 ± 10  23 ± 9  
Percentages of Viable Cells With the Following Phenotype
Cytokine ConditionsNumber of ExptsFold Increase*3434+45lo71lo34+45lo71hi34+45hi71hi
SCF 3  0.27 ± 0.14-151 7 ± 4  79 ± 6  4 ± 2  1 ± 1  
FL  2  0.21, 0.15-151 20, 11  62, 66  3, 13  1, 4  
IL-3  0.56 ± 0.17  46 ± 14  29 ± 15  19 ± 6 3 ± 2  
SCF + FL  3  0.43 ± 0.17  9 ± 4 56 ± 14  14 ± 7  12 ± 6   
SCF + IL-3  1.48 ± 0.88  31 ± 17  47 ± 19  24 ± 9 8 ± 4  
FL + IL-3  2  2.9, 1.9  17, 57 31, 13  33, 22  14, 6  
SCF + IL-3 + FL 5  1.96 ± 1.05  24 ± 14  19 ± 9  29 ± 10  23 ± 9  

*Represents the fold increase in cell number after 5 days in culture; calculated by dividing the number of viable cells recovered at day 5 by the number of cells seeded on day 0; a value less than 1 indicates a decrease in cell number.

F0-151

Values represent the mean ± SD for experiments performed three times or more; for experiments performed only twice, both values are reported.

Fig. 4.

Telomerase activity in subpopulations of cells present after 5 days in cultures of purified candidate HSC from adult marrow. See also Fig 3G. (A) CHAPS extracts from BM4-derived cells (lanes 1 to 10): CD34 fraction (lanes 1 and 2), CD34+fraction (lanes 3 and 4), CD34+CD45RAloCD71lo fraction (lanes 5 and 6), CD34+CD45RAloCD71hi fraction (lanes 7 and 8), and CD34+CD45RAhiCD71hi cells and (lanes 9 and 10); CHAPS extracts from BM1-derived cells (lanes 11 to 14): CD34 fraction (lanes 11 and 12) and CD34+ fraction (lanes 13 and 14). All extracts were generated from 1,000 cells.

Fig. 4.

Telomerase activity in subpopulations of cells present after 5 days in cultures of purified candidate HSC from adult marrow. See also Fig 3G. (A) CHAPS extracts from BM4-derived cells (lanes 1 to 10): CD34 fraction (lanes 1 and 2), CD34+fraction (lanes 3 and 4), CD34+CD45RAloCD71lo fraction (lanes 5 and 6), CD34+CD45RAloCD71hi fraction (lanes 7 and 8), and CD34+CD45RAhiCD71hi cells and (lanes 9 and 10); CHAPS extracts from BM1-derived cells (lanes 11 to 14): CD34 fraction (lanes 11 and 12) and CD34+ fraction (lanes 13 and 14). All extracts were generated from 1,000 cells.

Close modal

To further investigate the relationship between telomerase activity and cell proliferation in hematopoietic progenitors, we used PKH26 to track cell divisions at the level of single cells. Sorted candidate HSC were labeled with PKH26, a fluorescent dye that stably incorporates into the lipid bilayer and is diluted among the daughter cells with each successive cell division. After 8 days of culture in SCF + FL + IL-3, cells were sorted into PKHhi and PKHlofractions (Fig 5A). Telomerase activity in PKHlo cells was 5 to 10 times higher than the ones in PKHhi cells (Fig 5B), indicating that viable cells that remained quiescent in cytokine-stimulated cultures did not express detectable levels of telomerase.

Fig. 5.

PKH26 staining of purified candidate HSC before and after culture in SCF + IL-3 + FL. (A) PKH26 was incorporated into the lipid bilayer of purified candidate HSC at day 0. On day 8, PKH26 intensity was analyzed again and cells were sorted into PKHlo (gate1) and PKHhigh fractions (gate2) for TRAP. The cells in the PKHlo fraction have undergone several rounds of division, resulting in diminished dye fluorescence. (B) Telomerase activity in PKHhi and PKHlocells. PKHhi and PKHlo cells were sorted from BM1 after 8 days of culturing SCC in SCF + FL + IL-3. TRAP assay was performed on CHAPS extracts equivalent to 1,000 cells in the absence (−) and presence (+) of RNase A.

Fig. 5.

PKH26 staining of purified candidate HSC before and after culture in SCF + IL-3 + FL. (A) PKH26 was incorporated into the lipid bilayer of purified candidate HSC at day 0. On day 8, PKH26 intensity was analyzed again and cells were sorted into PKHlo (gate1) and PKHhigh fractions (gate2) for TRAP. The cells in the PKHlo fraction have undergone several rounds of division, resulting in diminished dye fluorescence. (B) Telomerase activity in PKHhi and PKHlocells. PKHhi and PKHlo cells were sorted from BM1 after 8 days of culturing SCC in SCF + FL + IL-3. TRAP assay was performed on CHAPS extracts equivalent to 1,000 cells in the absence (−) and presence (+) of RNase A.

Close modal
Telomerase activity in fetal liver CD34+CD38 cells.

Although telomerase activity was upregulated in 5-day cultures of adult marrow candidate HSC stimulated by SCF, IL-3, and FL, the activity was found to reside predominantly in the proliferating cells containing mainly committed progenitors. To address the question of whether cycling stem cells express telomerase activity, we examined telomerase expression in CD34+CD38 candidate HSC from fetal liver. Higher telomerase activity was detected in the fetal liver CD34+CD38 cells than those from adult bone marrow (Fig 6). Pooled data from three different samples showed that the activity in fetal liver CD34+CD38 cells ranged from 0.5% to 1.5% of that found in 293 cells, whereas in adult bone marrow the activity was at most 0.3% of that present in 293 cells. These results suggest that either all or a subfraction of cycling fetal liver stem cells express telomerase activity.

Fig. 6.

Comparison of telomerase activity in freshly isolated CD34+CD38 cells from fetal liver and adult marrow. TRAP assay performed on CHAPS extracts equivalent to 1,000 cells in the absence (−) and presence (+) of RNase A. CD34+CD38 cells from adult marrow (lanes 1 and 2) and fetal liver (lanes 3 and 4). Lysis buffer (LB) served as the negative control (lane 5), whereas 293 cells at the equivalent of 20 cells (lane 6) and 10 cells (lane 7) served as the positive controls.

Fig. 6.

Comparison of telomerase activity in freshly isolated CD34+CD38 cells from fetal liver and adult marrow. TRAP assay performed on CHAPS extracts equivalent to 1,000 cells in the absence (−) and presence (+) of RNase A. CD34+CD38 cells from adult marrow (lanes 1 and 2) and fetal liver (lanes 3 and 4). Lysis buffer (LB) served as the negative control (lane 5), whereas 293 cells at the equivalent of 20 cells (lane 6) and 10 cells (lane 7) served as the positive controls.

Close modal

The ability to induce or enhance telomerase activity may be important in maintaining the replicative potential of normal stem cells found in self-regenerating tissues such as those of the hematopoietic system.28,29 The studies reported here were aimed to investigate telomerase expression in the most primitive hematopoietic cells in humans. We confirmed our previous results regarding the low level of telomerase activity in freshly isolated “candidate” HSC with the CD34+CD45RAloCD71lophenotype from adult marrow.28 These sorted cells are highly enriched (several hundred-fold when compared with unpurified cells) in long-term culture-initiating cells (LTC-IC), arguably the best in vitro assay for human stem cells.38,39Unfortunately, most bone marrow cells with a CD34+CD45RAloCD71lo phenotype are unable to initiate long-term cultures, and rare committed progenitors from the adult bone marrow also share this phenotype.32 The latter, which are actively proliferating, could contribute partially or completely to the low but readily detectable levels of telomerase in purified candidate HSC before culture.

In the present study, we found that the level of telomerase activity in CD34+CD45RAloCD71lo cells sorted from cytokine-stimulated cultures was reduced as compared with that in freshly isolated cells with the same phenotype. On the other hand, telomerase activity was increased in cultured candidate HSC concomitantly with the upregulation of CD45RA and CD71 expression. By sorting various subpopulations after stimulation with SCF, FL, and IL-3 for 5 days, we found that telomerase activity was mainly confined to CD34+CD45RAloCD71hi and CD34+CD45RAhiCD71hi cells, which are known to be enriched in cycling progenitors committed to differentiate into the erythroid and myeloid lineages, respectively.32 In addition, tracking cellular division by PKH fluorescence confirmed that telomerase activity was confined to cells that had proliferated in culture. Cells with a CD34+CD45RAloCD71lo phenotype present after 5 days in cytokine culture could represent a population that failed to respond to SCF, FL, and IL-3 stimulation and remained quiescent or exited from the cell cycle. In both cases, telomerase activity is expected to be low in view of the data describing upregulation of telomerase activity upon entry into the cell cycle.35-37 40 

Because cycling stem cells are extremely rare in the adult bone marrow,30,33 and because our culture conditions are unable to induce the selective self-renewal of adult bone marrow candidate stem cells, we next examined telomerase expression in CD34+CD38 cells from fetal liver. It has been shown that the proliferative potential of hematopoietic cells changes during ontogeny and that candidate HSC from fetal liver contain a very high proportion of cycling cells as compared with candidate HSC from bone marrow.33 Our finding that CD34+CD38 fetal liver cells express readily detectable levels of telomerase activity strongly suggests that such cycling candidate HSC express telomerase activity. In view of the loss of telomerase DNA in hematopoietic cells with age,6 this observation can be explained by assuming that the measurable telomerase activity is not preventing the overall telomere shortening in candidate HSC.31 Alternatively, telomerase could be expressed in only a proportion of the cells. If the latter hypothesis is correct, then identification and selective expansion of such telomerase positive clones could be useful in transplantation and gene transfer protocols because their progeny would possibly maintain a high proliferative potential. To address this issue, more information about telomerase expression in single CD34+CD38 cells from fetal liver and the in vivo of the telomerase levels detected by telomerase assays is urgently needed. Antibodies to the telomerase reverse transcriptase protein15 16 could possibly be used to address this issue.

In our study we found that in day-5 cultures, CD34+ cells expressed higher telomerase activity than CD34 cells. One possible explanation for this observation is that as CD34+ differentiate, their telomerase activity is downregulated together with their proliferative potential. Similarly, freshly isolated CD34 cells from adult marrow also have lower telomerase activity compared with CD34+71+ cells, and when the latter were placed in culture over a period of 10 days, their telomerase activity declined.28 One recent report also shows that leukemic cell lines lose telomerase activity when induced to differentiate.40 41 

In a couple of transgenic mouse models, the reactivation of telomerase activity was correlated with tumorigenesis.42,43 However, the role of telomerase in normal somatic cells is still largely unknown. Telomerase activity is expressed in germline cells and is required to maintain telomere length and preserve the unlimited proliferative potential of these cells.44 In the hematopoietic system and skin epidermis,45,46 two other examples of self-renewing tissues, low levels of telomerase activity have been found. Possibly this activity could extend the proliferative potential of the stem cells in these tissues to a certain extent but not sufficient to confer immortality as telomeric DNA is still lost upon replication.47 In a similar manner, peripheral blood lymphocytes express low telomerase activity that is upregulated upon activation.29,35-37 Although the levels of telomerase activity once again appear insufficient to override telomeric decline, the enzyme activity could reduce the loss of telomeric DNA to allow repeated clonal expansion of immune cells upon antigenic stimulation.29 

In a recent study, telomerase activity in murine hematopoietic “candidate” stem cells and various progenitors was assayed on a single-cell basis and found to be associated with “self-renewal” potential, with lower levels in committed progenitors than in their pluripotent precursors.48 In contrast, we and others have consistently detected higher telomerase levels in committed progenitors relative to those observed in “candidate” stem cells using human hematopoietic tissues27-29 and this study. This discrepancy suggests that telomerase expression is regulated differently in murine versus human hematopoietic cells, a phenomenon that was previously observed with other cell types from these two species.43 49 

Because to date telomere length measurements are typically based on bulk DNA analysis using Southern hybridization, subtle changes in telomeric length on individual chromosomes could escape detection. This notion was recently confirmed in studies of cells from telomerase RNA knockout mice.44 On the basis of the distribution of telomere length in individual chromosomes of cultured hematopoietic cells using fluorescent in situ hybridization analysis, we proposed that telomerase in these cells may preferentially act on short telomeres to maintain a minimum number of repeats.50 If this is the case, the question of what telomere parameter, if any, is restricting the proliferative potential of adult hematopoietic cells becomes more pertinent. Possibly the low levels of telomerase that we measured are able to maintain the length of some but not many short telomeres. In this model, telomerase allows for a limited extension of the replicative lifespan of HSC. Studies in this general area using in situ hybridization to measure telomere length on individual chromosomes of clonally propagated hematopoietic cells in combination with assays of telomerase activity and protein expression should further clarify the role of telomerase in hematopoietic cells.

We thank Dr Nam Woo Kim (Geron Corperation) for generously sharing details on the modified TRAP assay before publication. Dr Mark Zijlmans is thanked for providing the fetal liver cells and Gayle Thornbury and Wieslawa Dragowska are thanked for their expertise in cell sorting.

Supported by National Institutes of Health Grant Nos. AI29524 and GM56162 and by a grant from Geron Corporation.

Address reprint requests to Peter M. Lansdorp, MD, PhD, Terry Fox Laboratory, British Columbia Cancer Agency, 601 W 10th Ave, Vancouver, BC, V5Z 1L3 Canada.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
Blackburn
 
EH
Telomeres: No end in sight.
Cell
77
1994
621
2
Zakian
 
VA
Telomeres: Beginning to understand the end.
Science
270
1995
1601
3
Harley
 
CB
Futcher
 
AB
Greider
 
CW
Telomeres shorten during ageing of human fibroblasts.
Nature
345
1990
458
4
Allsopp
 
RC
Vaziri
 
H
Patterson
 
C
Goldstein
 
S
Younglai
 
EV
Futcher
 
AB
Greider
 
CW
Harley
 
CB
Telomere length predicts replicative capacity of human fibroblasts.
Proc Natl Acad Sci USA
89
1992
10114
5
Vaziri
 
H
Schachter
 
F
Uchida
 
I
Wei
 
L
Zhu
 
X
Effros
 
R
Cohen
 
D
Harley
 
CB
Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes.
Am J Hum Genet
52
1993
661
6
Vaziri
 
H
Dragowska
 
W
Allsopp
 
RC
Thomas
 
TE
Harley
 
CB
Lansdorp
 
PM
Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age.
Proc Natl Acad Sci USA
91
1994
9857
7
Levy
 
MZ
Allsopp
 
RC
Futcher
 
AB
Greider
 
CW
Harley
 
CB
Telomere end-replication problem and cell aging.
J Mol Biol
225
1992
951
8
Lingner
 
J
Cooper
 
JP
Cech
 
TR
Telomerase and DNA end replication: No longer a lagging strand problem?
Science
269
1995
1533
9
Harley
 
CB
Telomere loss: Mitotic clock or genetic time bomb?
Mutat Res
256
1991
271
10
Greider
 
CW
Blackburn
 
EH
A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis.
Nature
337
1989
331
11
Singer
 
MS
Gottschling
 
DE
TLC1: Template RNA component of Saccharomyces cerevisiae telomerase.
Science
266
1994
404
12
McEachern
 
MJ
Blackburn
 
EH
Runaway telomere elongation caused by telomerase RNA gene mutations.
Nature
376
1995
403
13
Blasco
 
MA
Funk
 
W
Villeponteau
 
B
Greider
 
CW
Functional characterization and developmental regulation of mouse telomerase RNA.
Science
269
1995
1267
14
Feng
 
J
Funk
 
WD
Wang
 
S-S
Weinrich
 
SL
Avilion
 
AA
Chiu
 
C-P
Adams
 
RR
Chang
 
E
Allsopp
 
RC
Yu
 
J
Le
 
S
West
 
MD
Harley
 
CB
Andrews
 
WH
Greider
 
CW
Villeponteau
 
B
The RNA component of human telomerase.
Science
269
1995
1236
15
Nakamura
 
TM
Morin
 
GB
Chapman
 
KB
Weinrich
 
SL
Andrews
 
WH
Lingner
 
J
Harley
 
CB
Cech
 
TR
Telomerase catalytic subunit homologs from fission yeast and human.
Science
277
1997
955
16
Meyerson
 
M
Counter
 
CM
Eaton
 
EN
Ellisen
 
LW
Steiner
 
P
Dickinson Caddle
 
S
Ziaugra
 
L
Beijersbergen
 
RL
Davidoff
 
MJ
Liu
 
Q
Bacchetti
 
S
Haber
 
DA
Weinberg
 
RA
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.
Cell
90
1997
785
17
Kim
 
NW
Piatyszek
 
MA
Prowse
 
KR
Harley
 
CB
West
 
MD
Ho
 
PLC
Coviello
 
GM
Wright
 
WE
Weinrich
 
SL
Shay
 
JW
Specific association of human telomerase activity with immortal cells and cancer.
Science
266
1994
2011
18
Wright
 
WE
Piatyszek
 
MA
Rainey
 
WE
Byrd
 
W
Shay
 
JW
Telomerase activity in human germline and embryonic tissues and cells.
Dev Genet
18
1996
173
19
Counter
 
CM
Hirte
 
HW
Bacchetti
 
S
Harley
 
CB
Telomerase activity in human ovarian carcinoma.
Proc Natl Acad Sci USA
91
1994
2900
20
Hiyama
 
E
Gollahon
 
L
Kataoka
 
T
Kuroi
 
K
Yokoyama
 
T
Gazdar
 
AF
Hiyama
 
K
Piatyszek
 
MA
Shay
 
JW
Telomerase activity in human breast tumors.
J Natl Cancer Inst
88
1996
116
21
Tahara
 
H
Nakanishi
 
T
Kitamoto
 
M
Nakashio
 
R
Shay
 
JW
Tahara
 
E
Kajiyama
 
G
Ide
 
T
Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinomas.
Cancer Res
55
1995
2734
22
Hiyama
 
K
Hiyama
 
E
Ishioka
 
S
Yamakido
 
M
Inai
 
K
Gazdar
 
AF
Piatyszek
 
MA
Shay
 
JW
Telomerase activity in small-cell and non-small-cell lung cancers.
J Natl Cancer Inst
87
1995
895
23
Sommerfeld
 
HJ
Meeker
 
AK
Piatyszek
 
MA
Bova
 
GS
Shay
 
JW
Coffey
 
DS
Telomerase activity: A prevalent marker of malignant human prostate tissue.
Cancer Res
56
1996
218
24
Hiyama
 
E
Hiyama
 
K
Yokoyama
 
T
Matsuura
 
Y
Piatyszek
 
MA
Shay
 
JW
Correlating telomerase activity levels with human neuroblastoma outcomes.
Nat Med
1
1995
249
25
Nilsson
 
P
Mehle
 
C
Remes
 
K
Roos
 
G
Telomerase activity in vivo in human malignant hematopoietic cells.
Oncogene
9
1994
3043
26
Counter
 
CM
Gupta
 
J
Harley
 
CB
Leber
 
B
Bacchetti
 
S
Telomerase activity in normal leukocytes and in hematologic malignancies.
Blood
85
1995
2315
27
Broccoli
 
D
Young
 
JW
de Lange
 
T
Telomerase activity in normal and malignant hematopoietic cells.
Proc Natl Acad Sci USA
92
1995
9082
28
Chiu
 
C-P
Dragowska
 
W
Kim
 
NW
Vaziri
 
H
Yui
 
J
Thomas
 
TE
Harley
 
CB
Lansdorp
 
PM
Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow.
Stem Cells
14
1996
239
29
Hiyama
 
K
Hirai
 
Y
Kyoizumi
 
S
Akiyama
 
M
Hiyama
 
E
Piatyszek
 
MA
Shay
 
JW
Ishioka
 
S
Yamakido
 
M
Activation of telomerase in human lymphocytes and hematopoietic progenitor cells.
J Immunol
155
1995
3711
30
Lansdorp
 
PM
Dragowska
 
W
Maintenance of hematopoiesis in serum-free bone marrow cultures involves sequential recruitment of quiescent progenitors.
Exp Hematol
21
1993
1321
31
Lansdorp
 
PM
Self renewal of stem cells.
Biol Blood Marrow Transplant
3
1997
171
32
Lansdorp
 
PM
Dragowska
 
W
Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow.
J Exp Med
175
1992
1501
33
Lansdorp
 
PM
Dragowska
 
W
Mayani
 
H
Ontogeny-related changes in proliferative potential of human hematopoietic cells.
J Exp Med
178
1993
787
34
Little
 
M-T
Langlois
 
S
Wilson
 
RD
Lansdorp
 
PM
Frequency of fetal cells in sorted subpopulations of nucleated erythroid and CD34+ hematopoietic progenitor cells from maternal peripheral blood.
Blood
89
1997
2347
35
Weng
 
N-P
Levine
 
BL
June
 
CH
Hodes
 
RJ
Regulated expression of telomerase activity in human T lymphocyte development and activation.
J Exp Med
183
1996
2471
36
Igarashi
 
H
Sakaguchi
 
N
Telomerase activity is induced by the stimulation to antigen receptor in human peripheral lymphocytes.
Biochem Biophys Res Commun
219
1996
649
37
Buchkovich
 
KJ
Greider
 
CW
Telomerase regulation during entry into the cell cycle in normal human T cells.
Mol Biol Cell
7
1996
1443
38
Sutherland
 
HJ
Eaves
 
CJ
Eaves
 
AC
Dragowska
 
W
Lansdorp
 
PM
Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro.
Blood
74
1989
1563
39
Sauvageau
 
G
Lansdorp
 
PM
Eaves
 
CJ
Hogge
 
DE
Dragowska
 
WH
Reid
 
DS
Largman
 
C
Lawrence
 
HJ
Humphries
 
RK
Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells.
Proc Natl Acad Sci USA
91
1994
12223
40
Holt
 
SE
Wright
 
WE
Shay
 
JW
Regulation of telomerase activity in immortal cell lines.
Mol Cell Biol
16
1996
2932
41
Sharma
 
HW
Sokoloski
 
JA
Perez
 
JR
Maltese
 
JY
Sartorelli
 
AC
Stein
 
CA
Nichols
 
G
Khaled
 
Z
Telang
 
NT
Narayanan
 
R
Differentiation of immortal cells inhibits telomerase activity.
Proc Natl Acad Sci USA
92
1995
12343
42
Blasco
 
MA
Rizen
 
M
Greider
 
CW
Hanahan
 
D
Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis.
Nat Genet
12
1996
200
43
Broccoli
 
D
Godley
 
LA
Donehower
 
LA
Varmus
 
HE
de Lange
 
T
Telomerase activation in mouse mammary tumors: Lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation.
Mol Cell Biol
16
1996
3765
44
Blasco
 
MA
Lee
 
H-W
Hande
 
MP
Samper
 
E
Lansdorp
 
PM
DePinho
 
RA
Greider
 
CW
Telomere shortening and tumor formation by mouse cells lacking telomerase RNA.
Cell
91
1997
25
45
Harle-Bachor
 
C
Boukamp
 
P
Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes.
Proc Natl Acad Sci USA
93
1996
6476
46
Yasumoto
 
S
Kunimura
 
C
Kikuchi
 
K
Tahara
 
H
Ohji
 
H
Yamamoto
 
H
Ide
 
T
Utakoji
 
T
Telomerase activity in normal human epithelial cells.
Oncogene
13
1996
433
47
Holt
 
SE
Shay
 
JW
Wright
 
WE
Refining the telomere-telomerase hypothesis of aging and cancer.
Nat Biotechnol
14
1996
834
48
Morrison
 
SJ
Prowse
 
KR
Ho
 
P
Weissman
 
IL
Telomerase activity in hematopoietic cells is associated with self-renewal potential.
Immunity
5
1996
207
49
Prowse
 
KR
Greider
 
CW
Developmental and tissue-specific regulation of mouse telomerase and telomere length.
Proc Natl Acad Sci USA
92
1995
4818
50
Lansdorp
 
PM
Verwoerd
 
NP
van de Rijke
 
FM
Dragowska
 
V
Little
 
M-T
Dirks
 
RW
Raap
 
AK
Tanke
 
HJ
Heterogeneity in telomere length of human chromosomes.
Hum Mol Genet
5
1996
685
Sign in via your Institution